Q4 2025 SMS Pharmaceuticals Ltd Earnings Call Transcript
Key Points
- SMS Pharmaceuticals Ltd (BOM:532815) reported a 39% growth in PAT for FY25, marking one of its strongest earnings performances.
- The company launched Asia's largest dedicated and automated production block for ibuprofen, enhancing its production capabilities.
- Successful completion of EUGMP and US FDA audits reflects the company's strong compliance culture.
- Revenue for Q4 FY25 grew by 43% to INR248 crores, indicating strong recovery in demand and execution.
- The company has approved a new CapEx plan of INR250 crores to support expansion in existing and new products, aiming for a 20% revenue growth in FY26.
- The company is maintaining high inventory levels, which are almost seven to eight months of sales, leading to concerns about inventory management.
- SMS Pharmaceuticals Ltd (BOM:532815) has a debt of INR311 crores, with an annual interest payment of INR20 crores, impacting financial flexibility.
- The company is holding slow-moving inventory, including INR40 crores related to COVID products, which may not be easily liquidated.
- Asset turnover for FY25 was 0.67, below the company's target of 1, indicating room for improvement in asset utilization.
- The company faces pricing pressure in commodity products like ibuprofen, which could impact margins if not managed effectively.
Ladies and gentlemen, good day, and welcome to the SMS Pharmaceuticals Limited Q4 and FY25 Earnings Conference Call.
This conference call may contain forward-looking statements about the company, which are based on the beliefs, opinions and expectations of the company as on date of this call. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. (Operator Instructions) Please note that this conference is being recorded.
Today, we have with us Mr. Vamsi Krishna Potluri, Executive Director; Mr. Lakshmi Narayana Tammineed, Chief Financial Officer; Mr. Thirumalesh Tumma, Company Secretary and Compliance Officer.
I now hand the conference over to Mr. Vamsi Krishna Potluri, Executive Director. Thank you, and over to you, sir.
Good morning, everyone, and thank you for joining us on today's call. We appreciate your continued interest in SMS Pharma and the time you've taken to be with us this morning. I trust you
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
